STOCK TITAN

Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Davis Mark Steven reported acquisition or exercise transactions in this Form 4 filing.

Myriad Genetics director Mark Steven Davis received a grant of 59,701 restricted stock units (RSUs) of common stock. The award was granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan and carries no purchase price.

Each RSU represents a right to receive one Myriad Genetics common share and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this grant, Davis directly holds 106,665 shares of common stock, reflecting his updated ownership position.

Positive

  • None.

Negative

  • None.
Insider Davis Mark Steven
Role null
Type Security Shares Price Value
Grant/Award Common Stock 59,701 $0.00 --
Holdings After Transaction: Common Stock — 106,665 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 59,701 RSUs Restricted stock units granted to Mark Steven Davis on 2026-06-04
Total shares after grant 106,665 shares Direct common stock holdings following the reported transaction
Grant price per share $0.00 per share RSUs granted at no purchase price as equity compensation
restricted stock units financial
"Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Equity Incentive Plan financial
"granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
vests financial
"and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davis Mark Steven

(Last)(First)(Middle)
322 NORTH 2200 WEST

(Street)
SALT LAKE CITY UTAH 84116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026A59,701(1)A$0106,665D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.
Remarks:
By: Justin Hunter For: Mark S. Davis06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Myriad Genetics (MYGN) director Mark Steven Davis report on this Form 4?

Director Mark Steven Davis reported receiving 59,701 restricted stock units of Myriad Genetics common stock as a grant. The award was made under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan as part of his compensation, rather than an open-market stock purchase.

How many Myriad Genetics (MYGN) shares does Mark Steven Davis hold after this RSU grant?

After this grant, Mark Steven Davis directly holds 106,665 shares of Myriad Genetics common stock. This total reflects his ownership position following the addition of 59,701 restricted stock units awarded as compensation, which will convert into shares upon meeting the vesting conditions described in the filing.

What are the vesting terms for the 59,701 restricted stock units granted by Myriad Genetics (MYGN)?

The 59,701 restricted stock units vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. Each vested RSU entitles Mark Steven Davis to receive one share of Myriad Genetics common stock when the vesting condition is satisfied.

Did Mark Steven Davis buy or sell Myriad Genetics (MYGN) shares in the market in this Form 4?

No open-market buy or sell took place in this Form 4. The transaction is coded as a grant or award acquisition, meaning Davis received 59,701 restricted stock units at no cost as part of his equity compensation, rather than trading existing Myriad Genetics shares.

Under which plan were the new Myriad Genetics (MYGN) restricted stock units granted to Mark Steven Davis?

The restricted stock units were granted under Myriad Genetics’ 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. This plan provides equity-based compensation, and each of the 59,701 RSUs represents a contingent right to receive one share of the company’s common stock upon vesting.